A good set of numbers from Novartis overall, although looking deeper brings forth some vulnerabilities. The pharma and the eye businesses delivered promising performance, but Sandoz’s woes continued into the quarter and Cosentyx also showed slower growth. The top three performers were Cosentyx (+35%), Entresto (+126%) and Gilenya (+8%). We remain buyers of the stock, considering its healthy pipeline and unwavering efforts towards trying out novel things in the sector.
04 May 2018
Upbeat performance and FX benefit amid some concerning pockets
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Upbeat performance and FX benefit amid some concerning pockets
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
04 May 2018 -
Author:
Kamla Singh -
Pages:
4
A good set of numbers from Novartis overall, although looking deeper brings forth some vulnerabilities. The pharma and the eye businesses delivered promising performance, but Sandoz’s woes continued into the quarter and Cosentyx also showed slower growth. The top three performers were Cosentyx (+35%), Entresto (+126%) and Gilenya (+8%). We remain buyers of the stock, considering its healthy pipeline and unwavering efforts towards trying out novel things in the sector.